Novo Nordisk might deal with more pressure ahead due to installing competitors and looming patent threats for semaglutide, stated TD Cowen. The bank reduced the pharmaceutical stock to hold from buy. Expert Michael Nedelcovych likewise reduced his rate target to $42 from $45, which suggests a gain of simply 6%. Shares of Novo Nordisk have actually struggled of late. They slipped 22% this year and are down 50% in over the previous 12 months. NVO 1Y mountain NVO 1Y chart Nedelcovych stated Novo Nordisk is not prepared to blunt its loss of semaglutide exclusivity. While the Wegovy tablet uses a driver, he noted its capacity can not totally ideal the ship, particularly when thought about along with lagging Ozempic prescriptions and Novo Nordisk’s CagriSema trials– which have actually stopped working or underwhelmed. CagriSema is a treatment Novo Nordisk is establishing that intends to use more impact weight-loss results versus semaglutide. “NVO is an ingenious business that can be relatively credited with opening the weight problems market’s capacity. However business deals with massive difficulties– initially from top quality competitors, then from semaglutide LOE– and it is no longer clear the pipeline can respond to the call,” Nedelcovych composed. “CagriSema, amycretin, ziltivekimab all have significant capacity, however do not integrate to develop an engaging post-sema trajectory.” Novo Nordisk’s semaglutide patent is protected through 2032. Nevertheless, it ends in a number of nations later on this month. Nedelcovych likewise thinks that Novo Nordisk’s semaglutide patent expiration might start to weigh more greatly on financier mind starting this year. While GLP-1 compounding is most likely to subside, the expert anticipates an increase in top quality competitors. “Regrettably, to the most jaundiced eye, success of Wegovy Tablet merely develops a bigger hole to be completed the not-too-distant future,” he composed. “For Wegovy’s franchise, the increase of the money pay market and decrease in net rate might blunt the effect of patent expiration down the roadway, however it is unclear that a longer, slower decrease through the 2030s would be seen more positively by financiers.” The expert included the Novo Nordisk deals with strong competitive pressures and it stays less and less most likely that the business will maintain its duopolies in the diabetes and weight problems treatment companies.
Related Articles
Add A Comment